I.D.B. Radiopharmacy

IDB Holland, commonly known as I.D.B. Radiopharmacy, is a specialized manufacturer and distributor of medical isotopes and radiopharmaceuticals based in the Netherlands. The company is a global leader in the production of non-carrier-added Lutetium-177 (n.c.a. Lu-177), marketed under the brand name LuMark, which is essential for Targeted Radionuclide Therapy (TRT). Their products are primarily used in the treatment of neuroendocrine tumors and prostate cancer, serving a worldwide network of hospitals and pharmaceutical companies. In 2018, IDB Holland was acquired by Curium, a global nuclear medicine giant, to enhance its therapeutic radiopharmaceutical portfolio. The company maintains a state-of-the-art GMP-certified manufacturing facility to ensure the highest standards of radiopharmaceutical production.